

Journal of Visualized Experiments

Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules --Manuscript Draft--

Manuscript Number:	JoVE53079R1
Full Title:	Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules
Article Type:	Methods Article - JoVE Produced Video
Keywords:	composite scaffold; Polymer; hydrogel; biochemicals; encapsulation; temporal; spatial; sustained release; topography
Manuscript Classifications:	10.1.293.140: Biomedical Engineering; 5.2.319.300: Drug Delivery Systems; 5.5.240.311.500: Tissue Engineering
Corresponding Author:	Evelyn KF Yim, Ph.D. National University of Singapore Singapore, - SINGAPORE
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	bieykfe@nus.edu.sg
Corresponding Author's Institution:	National University of Singapore
Corresponding Author's Secondary Institution:	
First Author:	Marie Francene Arnobit Cutiongco, M.Eng.
First Author Secondary Information:	
Other Authors:	Marie Francene Arnobit Cutiongco, M.Eng. Benjamin Kim Kiat Teo, Ph.D.
Order of Authors Secondary Information:	
Abstract:	Various scaffolds used in tissue engineering require the incorporation of controlled biochemical environment to mimic the physiological cell niche. Interfacial polyelectrolyte complexation (IPC) fibers can be used for controlled delivery of various biological agents such as small molecule drugs, cells, proteins and growth factors. The simplicity of the methodology in making IPC fibers gives flexibility in its application for controlled biomolecule delivery. Here, we describe a method of incorporating IPC fibers into two different polymeric scaffolds, hydrophilic polysaccharide and hydrophobic polycaprolactone, to create a multi-component composite scaffold. We showed that IPC fibers can be easily embedded into these polymeric structures, enhancing the capability for sustained release and improved preservation of biomolecules. We also created a composite polymeric scaffold with topographical cues and sustained biochemical release that can have synergistic effects on cell behavior. Composite polymeric scaffolds with IPC fibers represent a novel and simple method of recreating the cellular niche.
Author Comments:	We will be sending the Author License Agreement through fax.
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date to satisfy grant requirements, please indicate the date below and explain in your cover letter.	
If this article needs to be filmed by a certain date to due to	

author/equipment/lab availability, please indicate the date below and explain in your cover letter.	
---	--

Evelyn K.F. Yim, Ph.D
Associate Professor
Department of Biomedical Engineering
Faculty of Engineering
National University of Singapore

19 December 2014

Editorial Board
Journal of Visualized Experiments (JoVE) Bioengineering
One Alewife Center, Suite 200
Cambridge, Massachusetts 02140

Dear JoVE Bioengineering Editorial Board,

We are pleased to submit our original research article titled “Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules” for publishing in Journal of Visualized Experiments. We thank Dr. Eric Veien for his kind invitation to submit our work for consideration in JoVE.

In tissue engineering and regenerative medicine, the ultimate aim is to provide a proper structural and biological environment that mimics the natural physiological milieu. While numerous scaffolds have shown the structural capacity to sustain adherent cell growth, they lack a controlled biochemical microenvironment that can stimulate sustained delivery of protein-based growth factors. Methodologies for protein delivery waste expensive growth factors due to lack of encapsulation efficiency and deterioration of bioactivity after release. Interfacial polyelectrolyte complexation (IPC) fibers represent a simple and efficient way to deliver biomolecules such as growth factors. Through occurrence in aqueous and ambient conditions, IPC fibers also help to retain biomolecule activity. IPC fibers can be combined with hydrophilic and hydrophobic polymeric systems to create scaffolds

with sustained growth factor delivery. Using this simple and flexible methodology, we show how to create different composite scaffolds by embedding IPC fibers in polysaccharide hydrogel and hydrophobic polycaprolactone scaffold. Using this method, sustained release of two bioactive factors, vascular endothelial growth factor and nerve growth factor, can be achieved. These composite scaffolds of polycaprolactone and IPC fibers can also contain both topography and sustained biochemical release to create a synergistic cellular environment.

We believe that this versatile and simple methodology of creating holistic scaffolds that recapitulate the cellular microenvironment would be more beneficial to the scientific community when shown in the visual format of JoVE.

If further information is needed during the review, I would prefer to be contacted by email (eyim@nus.edu.sg). Thank you for your consideration.

Yours sincerely,



Evelyn K.F. Yim

Associate Professor

Tel: (65) 6516 7322

Fax: (65) 6872 3069

E-mail: eyim@nus.edu.sg

TITLE:

Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules

AUTHORS:

CUTIONGCO, Marie Francene A.
Department of Biomedical Engineering
National University of Singapore
biemfac@nus.edu.sg

TEO, Benjamin Kim Kiat
Mechanobiology Institute, Singapore
National University of Singapore
mbiteok@nus.edu.sg

CORRESPONDING AUTHOR:

YIM, Evelyn King Fai
Department of Biomedical Engineering
Department of Surgery
Mechanobiology Institute, Singapore
National University of Singapore
eyim@nus.edu.sg
+65 6516 7322

KEYWORDS:

composite scaffold, polymer, hydrogel, biochemicals, encapsulation, temporal, spatial, sustained release, topography

SHORT ABSTRACT:

Scaffolds for tissue engineering need to recapitulate the complex biochemical and biophysical microenvironment of the cellular niche. Here, we show the use of interfacial polyelectrolyte complexation fibers as a platform to create composite, multi-component polymeric scaffolds with sustained biochemical release.

LONG ABSTRACT:

Various scaffolds used in tissue engineering require a controlled biochemical environment to mimic the physiological cell niche. Interfacial polyelectrolyte complexation (IPC) fibers can be used for controlled delivery of various biological agents such as small molecule drugs, cells, proteins and growth factors. The simplicity of the methodology in making IPC fibers gives flexibility in its application for controlled biomolecule delivery. Here, we describe a method of incorporating IPC fibers into two different polymeric scaffolds, hydrophilic polysaccharide and hydrophobic polycaprolactone, to create a multi-component composite scaffold. We showed that IPC fibers can be easily embedded into these polymeric structures, enhancing the capability for sustained release and improved preservation of biomolecules. We also created a composite polymeric scaffold with topographical cues and sustained biochemical

release that can have synergistic effects on cell behavior. Composite polymeric scaffolds with IPC fibers represent a novel and simple method of recreating the cellular niche.

INTRODUCTION:

The extracellular matrix has inherent biochemical and biophysical cues that direct cell behaviors. Mimicking this physiological three-dimensional (3D) microenvironment is a widely explored strategy for regenerative medicine and tissue engineering applications. For example, both naturally-derived and synthetic substrates have been modified with topographical cues as a means to mimic the biophysical cellular environment.¹ For example, polycaprolactone (PCL) scaffolds can be easily patterned by casting on patterned PDMS substrates.² However, most synthetic scaffolds inadequately recapitulate the controlled biochemical environment *in vivo*. Bulk or surface modification of synthetic materials only present biochemical cues for cell attachment but still lack temporal regulation of biochemical delivery.³ Thus, there is a need for optimal scaffolds that can mimic the temporally regulated biochemical delivery system of the extracellular matrix.

Biochemical delivery systems such as microspheres are plagued by problems of loss of bioactivity and low incorporation efficiency due to the severity and complexity of multi-step synthesis process.⁴⁻⁶ Alternative methods that use a one-step fabrication and incorporation method were proven to have excellent potential to create a favorable biochemical microenvironment without the accompanying inefficiency in incorporation and loss of bioactivity. One viable solution is the use of interfacial polyelectrolyte complexation (IPC) fibers to deliver and protect biological agents. When two oppositely charged polyelectrolyte aqueous solutions are brought together, IPC fibers can be drawn out from the interface. Virtually any type of hydrophilic biomolecule in aqueous solution can be added into either the negatively- or positively-charged polyelectrolyte solution, thus facilitating the incorporation of useful biomolecules into the IPC fiber during the complexation process. Furthermore, this process only requires aqueous and ambient conditions, thereby decreasing the risk of loss of bioactivity. Using this method, active growth factors^{2,7} even cells^{8,9} have been successfully delivered. In addition, the simple method of forming IPC fibers allows molding into any shape or orientation. The stability of such fibers has been advantageous in its incorporation into both hydrophobic² and hydrophilic polymers⁷ to create composite scaffolds. These composite scaffolds with IPC fibers are beneficial for creating a physiologically relevant biochemical environment while providing physical anchorage for cells.

In this study, we show a method to incorporate IPC fibers into a hydrophilic and a hydrophobic scaffold with topography for controlled release of active biomolecules. As a proof-of-concept, we incorporate IPC fibers made from chitosan and alginate into the biocompatible, non-immunogenic and non-antigenic pullulan-dextran hydrophilic hydrogel or the biocompatible polycaprolactone hydrophobic scaffold.

PROTOCOL:

1. PREPARATION OF POLYELECTROLYTE SOLUTIONS

1.1 Purify chitosan, as detailed in Liao et al. Briefly, create a 1% (w/v) solution of chitosan in 2% (v/v) acetic acid and vacuum filter using grade 93 filter paper. Neutralize the filtrate using 5M NaOH until the pH stabilized to 7. Centrifuge the precipitated chitosan at 1200 x g for 10 mins. Decant the supernatant and add deionized water to wash the chitosan. Repeat the centrifugation and washing step two more times. Freeze the precipitated chitosan at -80 °C and lyophilize overnight to obtain the purified form. Store purified chitosan in a dehumidified cabinet.

1.2 Weigh out 1 g of purified chitosan into a sterile tissue culture dish. Place the chitosan in the tissue culture dish as close as possible to the UV lamp in the biological safety cabinet and expose to UV light for 15 mins. Using sterile forceps, place the sterilized chitosan into a glass container. Dissolve chitosan using filtered 0.15M acetic acid to a final concentration between 0.5% and 1% (w/v).

1.3 Weigh out 0.1 g of alginic acid sodium salt and dissolve in 10 ml distilled deionized (DDI) water to obtain a 1% (w/v) solution. Mix the alginic acid sodium salt for at least 2 hours on the vortex mixer to ensure complete dissolution. Filter the alginate solution through 0.2 µm syringe filter. Store the alginate solution at 4 °C.

1.4 Reconstitute human recombinant growth factors such as vascular endothelial growth factor (VEGF) or beta - nerve growth factor (NGF), as recommended by manufacturer.

2. DRAWING OF IPC FIBERS

2.1 Mix proteins, growth factors or other biomolecules into 10-20 µl aliquot of the polyelectrolyte solution that has a similar net charge. Biological molecules with net negative charge (eg bovine serum albumin [BSA]) should be mixed with alginate solution. Biological molecules with net positive charge (eg VEGF) should be mixed with chitosan solution.

2.2 Place small aliquots (10-20 µl) of chitosan and alginate on a stable flat surface that is covered with parafilm. The droplets of chitosan and alginate should be placed in close proximity but not in contact with each other.

2.3 Lightly dip each tip on a pair of forceps into the chitosan and alginate droplets. Bring the droplets of polyelectrolytes together by pinching the forceps. When the droplets come into contact with each other, slowly pull the forceps vertically upward to draw the IPC fiber from the interface of the two droplets (Figure 1A).

2.4 Carefully place the end of the drawn IPC fiber on the forceps on a collector, such as a flat polymeric scaffold affixed on a rotating mandrel (see section 3 and 4). Rotate the mandrel at a fixed speed of 10 mm/s to allow formation of uniform and beadless IPC fibers. Increasing the speed of drawing the IPC fibers will form beads, which will cause a burst release of incorporated biochemical and premature fiber termination.¹⁰

2.5 To determine incorporation efficiency, collect all the remaining liquids left on the parafilm by diluting with 500 μ l of 1X phosphate buffered saline (PBS). Measure the protein or growth factor content in the residue through BCA assay (for BSA), ELISA (for VEGF and NGF) or an appropriate assay to detect incorporated biomolecule.

3. FABRICATION OF COMPOSITE HYDROGEL SCAFFOLD OF PULLULAN-DEXTRAN (PD) POLYSACCHARIDE AND IPC FIBERS

3.1 Fabricating sacrificial pullulan frame for IPC fiber collection

3.1.1 Weigh out pullulan polysaccharide and mix with distilled deionized (DDI) water to create a 20% (w/v) aqueous solution. Mix the pullulan solution overnight to ensure homogeneity.

3.1.2 Cast 15g of pullulan solution into a 10-cm diameter tissue culture polystyrene (TCPS) dish. Dry the pullulan solution overnight at 37 °C. Cut the pullulan films into 7 mm x 7 mm square frames.

3.2 Preparing pullulan-dextran polysaccharide solution

3.2.1 Create a 30% (w/v) solution of the polysaccharides pullulan and dextran (3:1 ratio) in DDI water. Mix overnight to ensure homogeneity of the polysaccharide solution. Slowly add in sodium bicarbonate to the polysaccharide solution to achieve a final concentration of 20% (w/v). Mix overnight to ensure homogeneity of the solution. Store the polysaccharide solution at 4 °C.

3.2 Collecting IPC fibers on pullulan frame

3.2.1 Affix the sacrificial pullulan frame (section 3.1) using an alligator clip. Stick the alligator clip and pullulan frame on the end of the rotating mandrel using plastic-coated adhesive tape. Rotate the mandrel with the affixed frame at a constant speed of 10 mm/s. The pullulan frame can be affixed onto the rotating mandrel in desired orientations.

3.2.2 Draw the IPC fibers using a pair of forceps (section 1) and attach the drawn end of the IPC fibers onto the rotating pullulan frame. Draw the IPC fibers at a constant speed. Upon reaching the terminal end of the IPC fiber, dry the fibers-on-frame construct overnight at room temperature.

3.3 Embedding IPC fibers into PD hydrogel scaffold

3.3.1 To crosslink 1 g of the pullulan-dextran solution, add 100 μ l of 11% (w/v) sodium trimetaphosphate aqueous solution and 100 μ l 10M sodium hydroxide.⁷ Mix the solution at 60 rpm using a stirplate for 1 to 2 mins. After the addition of sodium trimetaphosphate and sodium hydroxide, the polysaccharide solution will crosslink almost immediately. Pour the viscous polysaccharide solution onto the fibers-on-frame construct to fully embed the IPC fibers. Incubate the combined pullulan-dextran-IPC fibers (PD-IPC) at 60 °C for 30 mins to form a chemically crosslinked composite scaffolds (Figure 1B).

CAUTION: Perform step 3.3.2 in the fume hood and use proper protective equipment as

acetic acid is a corrosive and flammable.

3.3.2 To induce pore formation in the PD-IPC scaffold, submerge the whole scaffold in 20% (w/v) acetic acid for 20 mins.

3.3.3 Remove unreacted reagents by washing PD-IPC scaffolds in 1X PBS for 5 mins while shaking at 100 rpm. Repeat this step 2 times.

3.3.4 Remove the excess PBS and immediately freeze the PD-IPC scaffolds at -80 °C overnight. Lyophilize the scaffolds at least 24 hours before use in any controlled release or bioactivity assays.

4. FABRICATION OF COMPOSITE SCAFFOLD OF PCL AND IPC FIBERS

CAUTION: Dichloromethane is a hazardous material. Use the fume hood and personal protective equipment when handling dichloromethane.

4.1 Creating pristine and patterned PDMS substrates

4.1.1 Create a pristine polydimethylsiloxane (PDMS) elastomeric substrate using a piece of TCPS of desired dimension using soft lithography process. Create patterned PDMS substrates by using standard soft lithographic methods on poly(methyl methacrylate) templates with the desired topography.¹¹

4.2 Fabricating sacrificial PCL frame for IPC fiber collection

4.2.1 Weigh out PCL and dissolve in dichloromethane to create a 0.9% (w/v) solution. For every 1 cm² area of the PDMS substrate, drop 1 ml of 0.9% PCL solution. Allow all of the dichloromethane solvent to fully evaporate in the fume hood. Repeat the process of casting 0.9% PCL to thicken the film to the desired thickness. Remove the dried PCL film from the PDMS substrate. Create a hole in the PCL frame using a suitably-sized puncher.²

4.3 Collecting IPC fibers on the PCL frame

4.3.1 Affix the sacrificial PCL frame with hole (from 4.2.1) on an alligator clip. Stick the alligator clip onto the rotating mandrel by using plastic-coated adhesive tape. Attach the drawn end of the IPC fiber onto the PCL frame before starting the rotation at a constant speed of 10mm/s (section 2). After the end of IPC fiber drawing, dry the fiber-on-frame construct overnight at 4 °C.

4.4 Embedding fiber-on-frame construct into patterned PCL substrate

4.4.1 Drop 500 µl of 0.9% PCL solution onto the PDMS substrate to create a pristine or patterned PCL base, as required. Cast multiple layers of 0.9% PCL solution to obtain a scaffold with the desired thickness. Allow all of the dichloromethane solvent to fully evaporate in the fume hood.

4.4.2 Place the fiber-on-frame construct (section 4.3.1) on top of the PCL base. Add 0.9% PCL solution on the fiber-on-frame construct multiple times to get the desired thickness and fully embed the IPC fibers, fabricating a PCL-IPC composite scaffold

(Figure 1C).

5. MEASUREMENT OF RELEASE OF BIOLOGICAL AGENTS FROM COMPOSITE IPC SCAFFOLDS

5.1 Place composite PD-IPC or PCL-IPC scaffolds and stand-alone IPC fibers separately in a 24-well plate.

5.2 Immerse the scaffold and stand-alone IPC fibers with 500 μ l of 1X PBS. Incubate the samples at 37 °C. Collect PBS at various time points (release media) and replace with 500 μ l of 1X PBS.

5.3 Measure the amount of protein or growth factor in the release media using a BCA assay (BSA), ELISA (VEGF and NGF) or other appropriate assay to calculate the cumulative release profile for the incorporated biomolecule.

6. SEEDING OF CELLS ON COMPOSITE IPC SCAFFOLDS TO TEST BIOACTIVITY OF RELEASED BIOLOGICAL AGENTS

6.1 Sterilize the lyophilized PD-IPC or PCL-IPC composite scaffolds using UV light in the biological safety cabinet for at least 20 mins.

6.2 Use standard cell culture techniques to obtain a cell suspension of 2×10^5 cells in 200 μ l growth media. Seed the concentrated cell suspension onto the composite scaffolds. After 20 minutes, top-up the volume of growth media to fully submerge the scaffolds.

6.3 Measure cell activity through standard techniques such as Alamar blue metabolic activity assay, PC12 neurite outgrowth assay or immunofluorescence.

REPRESENTATIVE RESULTS:

In this article, we sought to create composite scaffolds with IPC fibers for the sustained release of various biomolecules. Characteristics of the biomolecules used in this study are found in Table 1. IPC fibers were first embedded into a hydrophilic PD hydrogel to create a PD-IPC composite scaffold (Figure 1B). Model molecule BSA was first tested to determine the feasibility of using a composite scaffold for controlled biomolecule release. BSA was incorporated into PD-IPC scaffolds with an efficiency of $45 \pm 0.97\%$. BSA released from the PD-IPC showed near-linear kinetics with an initial attenuated burst release followed by a concomitant steady state (Figure 2). After 2 months, BSA achieved a total release of 97%. In contrast, standalone IPC fibers exhibited a rapid release of 80% of BSA within 4 hours.

Next, we checked the release profile and bioactivity of VEGF using PD-IPC scaffolds. VEGF was incorporated with an efficiency of $75.5 \pm 2.7\%$, and showed a sustained release for at least 1 week (Figure 3A). Human umbilical vein endothelial cells (HUVECs) were seeded on the PD-IPC scaffolds to determine the bioactivity of VEGF. HUVECs on the PD-IPC scaffolds showed a significant increase in Alamar blue reduction and metabolic activity compared with plain PD scaffolds at day 1, indicating

good preservation of VEGF function after being released from PD-IPC scaffolds (Figure 3B). Alamar blue reduction at days 3, 6 and 7 decreased to achieve comparable levels with the plain PD scaffold (Figure 3B).

The PCL-IPC composite scaffolds were also tested for controlled release and compared with standalone IPC fibers. We incorporated NGF as a representative molecule into the PCL-IPC composite scaffolds with an incorporation efficiency of $66.38 \pm 2.71\%$. PCL-IPC composite scaffolds showed linear sustained release and approximately 80% cumulative release after 18 days (Figure 4A). On the other hand, IPC stand-alone fiber showed a 70% burst release within 24 hours followed by a stagnant release rate. Using a PC12 neurite outgrowth assay, we examined the bioactivity of the released NGF (Figure 4B). The neurite outgrowth of PC12 cells grown on PCL-IPC composite scaffold release media showed similar levels with PC12 cells cultured in 30 ng/ml NGF supplemented media. This indicates that the released NGF remained bioactive for at least 7 days.

Combination of topography and sustained growth factor delivery may mimic the cellular microenvironment better. The versatile methodology of PCL-IPC fabrication allowed the fabrication of a biochemically- and topographically-controlled composite scaffold. We fabricated a PCL-IPC composite scaffold with nano-sized gratings structure (NP-PCL-IPC scaffold). We observed the synergistic effect of topography and sustained NGF release by assessing neuronal differentiation of human mesenchymal stem cells (hMSCs) (Figure 5). hMSCs cultured on the NP-PCL-IPC composite scaffolds showed higher expression of the Microtubule associated protein 2 (MAP2), indicative of neuronal differentiation. On the other hand, MAP2 protein expression was substantially lower in hMSCs cultured on PCL-IPC with only NGF release or patterned PCL (NP-PCL).

FIGURE LEGENDS:

Figure 1. Incorporation of IPC fibers into hydrophilic and hydrophobic scaffolds.

(A) Drawing of IPC fibers at the interface of positively (chitosan) and negatively (alginate) charged polyelectrolyte solutions. (B) Schematic diagram showing incorporation of IPC fibers in hydrophilic PD solution to create PD-IPC composite scaffold. (C) Schematic diagram showing incorporation of IPC fibers in hydrophobic PCL scaffold to create PCL-IPC composite scaffold. This figure is adapted from Cutiongco et al., 2014.⁷

Figure 2. Controlled release of BSA from PD-IPC composite scaffold. BSA was incorporated into PD-IPC composite scaffolds and its release was measured at various time points using BCA assay. Cumulative BSA released is provided as a percentage of the total amount of BSA (in μg) incorporated in the IPC fibers and are presented as mean percentage \pm standard deviation. This figure is adapted from Cutiongco et al., 2014.⁷

Figure 3. Controlled release and bioactivity of VEGF from PD-IPC composite scaffold. (A) Cumulative release profile of VEGF from PD-IPC composite scaffolds.

VEGF release was measured at various time points using ELISA specific for VEGF. (B) Cell viability of endothelial cells grown on PD-IPC composite scaffolds, as measured by Alamar blue metabolic assay. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test. *denotes $p < 0.05$. This figure is adapted from Cutiongco et al., 2014.⁷

Figure 4. Controlled release and bioactivity of NGF from PCL-IPC composite scaffold. (A) Cumulative release profile of NGF from PCL-IPC composite scaffolds. NGF release was measured at various time points using ELISA specific for NGF. Insert shows cumulative release profile of NGF from PCL-IPC scaffold for the first 8 hours. (B) Bioactivity of NGF as measured by outgrowth of PC12 neural cells. PC12 outgrowth was measured through image analysis. This figure is adapted from Teo et al., 2014.²

Figure 5. Differentiation of hMSC on NP-PCL-IPC scaffold. Confocal scanning microscopy image of hMSC cultured on different composite scaffolds. (A) NP-PCL-IPC, (B) NP-PCL, (C) PCL-IPC, (D) Pristine PCL scaffolds. Green stain denotes MAP2, a neuronal lineage marker. Red stain denotes F-actin, showing the cellular cytoskeleton. Blue stain denotes the nucleus. This figure is adapted from Teo et al., 2014.²

Table 1. Characteristics of biochemicals used for controlled release from composite IPC scaffolds.

DISCUSSION:

IPC fibers are formed by the interaction of two oppositely charged polyelectrolytes. The process utilizes the extraction of the complex from the interface of the polyelectrolytes, facilitating a self-assembly process for stable fiber formation. The mechanism of IPC fiber formation ensures that any biomolecule added into a similarly charged polyelectrolyte can be incorporated during the complexation process.^{10,12} Conversely, addition of a biomolecule into the oppositely charged polyelectrolyte will result in instantaneous precipitation. The simple fabrication methodology for IPC fibers lends versatility in incorporating various biological materials such as cells, growth factors and small molecules. This critical feature of IPC fibers was also observed in both the PD-IPC and PCL-IPC composite scaffolds, where growth factors with different physical and biomolecular properties (charge and molecular weight) were incorporated with high efficiency. In contrast, encapsulation efficiency using microsphere methodologies for VEGF and NGF can be as low as 16%⁶ and 8%¹³, respectively.

Both PD-IPC and PCL-IPC scaffolds also demonstrated temporal control of biomolecule release. VEGF from PD-IPC scaffolds showed linear release for at least 7 days. In contrast, reported VEGF release profiles from polymeric microspheres showed an initial burst release within 24 hours, releasing at least 60% of the total VEGF content.^{5,14,15} Similarly, NGF was shown to have sustained growth factor delivery from PCL-IPC scaffolds, while other polymeric-based growth factor delivery systems show a plateau of release from 20 days of release.^{13,16} Presumably, the different components of the composite scaffolds both contribute to growth factor release kinetics. Polymer relaxation mechanisms, porosity and tortuosity can greatly affect the release of hydrophilic

biomolecules.¹⁷ In addition, the chemical characteristics of the polymeric scaffold may have electrostatic attraction and repulsion towards the growth factors that affects biomolecule release. Thus, the characteristics of the polymeric scaffold are critical in determining release profiles and biomolecules with temporally-controlled release. For instance, while the PD scaffold showed near-linear BSA release, a similar composite scaffold using poly(vinyl alcohol) hydrogel lacked permeability to BSA.¹⁸ Polymeric scaffolds that can be used in combination with IPC fibers may require preliminary testing to determine its permeability range.

In addition to controlled biochemical release, the capacity to retain the bioactivity of growth factors is an important feature for any biomolecule delivery system. The harsh alkaline environment of the PD solution and the presence of organic DCM solvent in PCL have the potential to degrade any sort of biomolecules. For example, microsphere delivery system that used dichloromethane showed a consistent trend of diminishing bioactivity with increasing timepoint due to the degradation of NGF.¹⁶ Nonetheless, we observed that the bioactivity of VEGF and NGF is maintained, further reiterating that a key advantage of IPC fibers are assimilated within the composite scaffolds.

The use of a sacrificial, biocompatible polysaccharide or polymeric frame that can be easily incorporated into the bulk scaffold gives the versatility to create a composite scaffold with multiple IPC fibers aligned in different configurations.⁷ Thus, it is necessary that the polymeric scaffolds to be applied with IPC fibers have the capacity for further assimilation into a bulk scaffold. The assimilation process is important in fully embedding IPC fibers into the polymeric scaffold. We observed this phenomenon in the sacrificial pullulan and PCL frames, which were both easily dissolved in the solvent of the bulk PD or PCL scaffold. Furthermore, the single-step method for IPC fabrication and biomolecule incorporation gives flexibility to the number of biomolecules that can be delivered by a single composite scaffold. The simplicity of the methodology also allows fine-tuning of the incorporation efficiency and release kinetics by changing polyelectrolyte identity or concentration. The natural polyelectrolytes chitosan and alginate were used due to its high charge density and similarity to various ECM carbohydrates found in animal tissues. Yet methylated collagen and terpolymer^{8,19} or chitin and alginate²⁰ may also be used for IPC fiber formation to varying effects. Multiple IPC fibers release different biochemical cues with different kinetics can also be achieved to create a multi-functional composite scaffold. For example, extracellular matrix proteins such as fibronectin loaded into IPC fibers may provide a platform for spatially controlled cell adhesion.⁷ Sustained release of antibiotics and growth factors are also desirable for tissue regeneration applications. This may be possible by using PCL-IPC, which can incorporate hydrophobic, small molecule drugs and hydrophilic, protein-based growth factors in different compartments of the composite scaffold.²

Our presented methodology also permitted the fabrication of a scaffold with both topographical and biochemical cues. We observed that the NP-PCL-IPC scaffold had the highest enhancement of hMSC differentiation into the neuronal lineage, implying that mimicking multiple aspects of the biophysical and biochemical cellular niche is beneficial in directing cell behavior. The ease of the presented methodology permits its

application to other patternable polymeric systems such as polyacrylamide²¹ or polyethylene glycol²², provided that the crosslinking process will not significantly affect IPC fiber integrity. For example, PD scaffolds were chosen in this study for its unique crosslinking mechanism that occurs in ambient and aqueous conditions.²⁴ This can potentially provide more physiologically relevant substrates for *in vitro* and *in vivo* studies. In addition, embedding IPC fibers in a composite scaffold can overcome the lack of mechanical strength of IPC fibers²³ by providing tensile strength. Indeed, PCL²⁵ was chosen for its high mechanical strength.

In summary, a simple method for creating composite scaffolds for biomolecule delivery was described. We demonstrated how IPC fibers can be used for sustained delivery of biomolecules without compromising its bioactivity and the incorporation efficiency. We showed this by creating composite scaffolds with two variations: PD-IPC and PCL-IPC scaffolds. Applicability of IPC fibers is not limited to incorporation in PD- and PCL-based scaffolds, but can be potentially extended to other polymeric systems and to deliver other biomolecules.

ACKNOWLEDGMENTS:

This work was supported by the Singapore National Research Foundation administered by one of its Research Centers of Excellence, the Mechanobiology Institute, Singapore. MFAC is supported by the Agency for Science, Technology and Research (Singapore) and National Agency for Research (France) joint program under project number 1122703037. BKKT is supported by the Mechanobiology Institute. We thank Mr. Daniel HC Wong for proof-reading the manuscript.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:


1. Annabi, N., Tamayol, A., et al. 25th Anniversary Article: Rational design and applications of hydrogels in regenerative medicine. *Adv. Mater.* **26** (1), 85–124, doi:10.1002/adma.201303233 (2014).
2. Teo, B.K.K., Tan, G.D.S. & Yim, E.K.F. The synergistic effect of nanotopography and sustained dual release of hydrophobic and hydrophilic neurotrophic factors on human mesenchymal stem cell neuronal lineage commitment. *Tissue Eng. Part A.* **20** (15-16), 2151–2161, doi:10.1089/ten.tea.2013.0382 (2014).
3. Lee, K., Silva, E. A. & Mooney, D.J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. *J. R. Soc. Interface.* **8** (55), 153–170, doi:10.1098/rsif.2010.0223 (2011).
4. Sun, Q., Chen, R.R., Shen, Y., Mooney, D.J., Rajagopalan, S. & Grossman, P.M. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. *Pharm. Res.* **22** (7), 1110–1116, doi:10.1007/s11095-005-5644-2 (2005).
5. Rui, J., Dadsetan, M., et al. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. *Acta Biomater.* **8** (2),

- 511–518, doi:10.1016/j.actbio.2011.10.001 (2012).
6. King, T.W. & Patrick, C.W. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. *J. Biomed. Mater. Res.* **51** (3), 383–390, (2000). doi:10.1002/1097-4636(20000905)51:3<383::AID-JBM12>3.0.CO;2-D
 7. Cutiongco, M.F.A., Tan, M.H., Ng, M.Y.K., Le Visage, C. & Yim, E.K.F. Composite pullulan-dextran polysaccharide scaffold with interfacial polyelectrolyte complexation fibers: A platform with enhanced cell interaction and spatial distribution. *Acta Biomater.* **10** (10), 4410–4418, doi:10.1016/j.actbio.2014.06.029 (2014).
 8. Yow, S.Z., Quek, C.H., Yim, E.K.F., Lim, C.T. & Leong, K.W. Collagen-based fibrous scaffold for spatial organization of encapsulated and seeded human mesenchymal stem cells. *Biomaterials.* **30** (6), 1133–1142, doi:10.1016/j.biomaterials.2008.11.003 (2009).
 9. Yim, E.K.F., Wan, A.C.A., Le Visage, C., Liao, I.C. & Leong, K.W. Proliferation and differentiation of human mesenchymal stem cell encapsulated in polyelectrolyte complexation fibrous scaffold. *Biomaterials.* **27** (36), 6111–6122, doi:10.1016/j.biomaterials.2006.07.037 (2006).
 10. Wan, A.C.A., Liao, I.C., Yim, E.K.F. & Leong, K.W. Mechanism of fiber formation by interfacial polyelectrolyte complexation. *Macromolecules.* **37** (18), 7019–7025, doi:10.1021/ma0498868 (2004).
 11. Yim, E.K.F., Reano, R., Pang, S., Yee, A., Chen, C. & Leong, K.W. Nanopattern-induced changes in morphology and motility of smooth muscle cells. *Biomaterials.* **26** (26), 5405–5413, doi:10.1016/j.biomaterials.2005.01.058 (2005).
 12. Liao, I.C., Wan, A.C., Yim, E.K.F. & Leong, K.W. Controlled release from fibers of polyelectrolyte complexes. *J. Control. Release.* **104** (2), 347–358 (2005). doi: 10.1016/j.jconrel.2005.02.013
 13. Sun, H., Xu, F., Guo, D. & Yu, H. Preparation and evaluation of NGF-microsphere conduits for regeneration of defective nerves. *Neurol. Res.* **34** (5), 491–497, doi:10.1179/1743132812Y.0000000037 (2012).
 14. Simón-Yarza, T., Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F. & Blanco-Prieto, M.J. PEGylated-PLGA microparticles containing VEGF for long term drug delivery. *Int. J. Pharm.* **440** (1), 13–18, doi:10.1016/j.ijpharm.2012.07.006 (2013).
 15. Patel, Z.S., Ueda, H., Yamamoto, M., Tabata, Y. & Mikos, A.G. In vitro and in vivo release of vascular endothelial growth factor from gelatin microparticles and biodegradable composite scaffolds. *Pharm. Res.* **25** (10), 2370–2378, doi:10.1007/s11095-008-9685-1 (2008).
 16. Sun, H., Xu, F., Guo, D. & Liu, G. In vitro evaluation of the effects of various additives and polymers on nerve growth factor microspheres. *Drug Dev. Int. Pharm.* **40** (4), 452–457, doi:10.3109/03639045.2013.767829 (2014).
 17. Lee, P.I. Kinetics of drug release from hydrogel matrices. *J. Control. Release.* **2**, 277–288, doi:10.1016/0168-3659(85)90051-3 (1985).
 18. Cutiongco, M.F.A., Choo, R.K.T., Shen, N.J.X., Chua, B.M.X., Sju, E., Choo, A.W.L., Le Visage, C., Yim, E.K.F. Composite scaffold of poly(vinyl alcohol) and interfacial polyelectrolyte complexation fibers for controlled biomolecule delivery.


- Front. Bioeng. Biotechnol.* **3** (3), 1-12, doi: 10.3389/fbioe.2015.00003.
19. Yow, S.Z., Lim, T.H., Yim, E.K.F., Lim, C.T. & Leong, K.W. A 3D Electroactive Polypyrrole-Collagen Fibrous Scaffold for Tissue Engineering. *Polymers*. **3** (1), 527–544, doi:10.3390/polym3010527 (2011).
 20. Leong, M.F., Toh, J.K.C., et al. Patterned prevascularised tissue constructs by assembly of polyelectrolyte hydrogel fibres. *Nat. Commun.* **4**, 2353, doi:10.1038/ncomms3353 (2013).
 21. Di Benedetto, F., Biasco, A., Pisignano, D. & Cingolani, R. Patterning polyacrylamide hydrogels by soft lithography. *Nanotechnology*. **16** (5), S165 (2005). doi: 1088/0957-4484/16/5/006
 22. Revzin, A., Russell, R.J., et al. Fabrication of poly(ethylene glycol) hydrogel microstructures using photolithography. *Langmuir*. **17** (18), 5440–5447 (2001). doi: 10.1021/la010075w
 23. Yim, E.K.F., Liao, I.C., & Leong, K.W. Tissue compatibility of interfacial polyelectrolyte complexation fibrous scaffold: evaluation of blood compatibility and biocompatibility. *Tissue Eng. Part A*. **13** (2), 423-433 (2007). doi: 10.1089/ten.2006.0113.
 24. Chaouat, M., Le Visage, C., Autissier, A., Chaubet, F., Letourneur, D., The evaluation of a small-diameter polysaccharide-based arterial graft in rats. *Biomaterials*. **27**, 5546-5553 (2006). doi: 10.1016/j.biomaterials.2006.06.032.
 25. Eshraghi, S. & Das, S. Mechanical and microstructural properties of polycaprolactone scaffolds with one-dimensional, two dimensional, and three-dimensional orthogonally oriented porous architectures produced by selective laser sintering. *Acta Biomater.* **6**, 2467-2476 (2010). doi: 10.1016/j.actbio.2010.02.002.

Figure 1

A



B



C




Figure 2




Figure 3




Figure 4




Figure 5




Table 1. Characteristics of biochemicals used for controlled release from composite IPC scaffolds.

Biologics	Molecular weight (kDa)	Isoelectric point	Net charge at IPC fiber formation
BSA	69	4.1	Negative
VEGF	43	8.5	Positive
NGF	13.5	9.5	Positive

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Pullulan	Hayashibara Inc Okayama Japan		Molecular weight (MW) 200 kDa. This material is pharmaceutical grade pullulan used to make pullulan frames and PD-IPC scaffolds.
Dextran	Sigma Aldrich	D1037	MW 500 kDa. This material is no longer being produced by Sigma Aldrich. Alternative suggested is catalog number 31392 (Sigma Aldrich). This material is used to make PD-IPC scaffolds.
Sodium Bicarbonate	Sigma Aldrich	S5761	Sodium bicarbonate must be slowly added to the pullulan-dextran polysaccharide solution. Rapid addition of sodium bicarbonate will result in precipitation.
Sodium Trimetaphosphate	Sigma Aldrich	T5508	This chemical is hygroscopic and must be stored in the dehumidifying cabinet. Aqueous solution of sodium trimetaphosphate must always be made fresh.
Sodium Hydroxide	Sigma Aldrich	S5881	This material is hazardous and must be handled with proper protective equipment such as nitrile gloves.
Chitosan	Sigma Aldrich	448877	MW 190-310 kDa. Acetylation degree of 75 to 85%. Purification of chitosan is required to create stable IPC fibers.

Acetic Acid	Merck		This can be replaced by another brand type. This material is corrosive and flammable. Protective equipment such as face shield, nitrile gloves, lab coat and shoe cover must be worn when handling this chemical in the fume hood.
Alginic acid sodium salt from brown algae, low viscosity	Sigma Aldrich	A2158	Dissolve in water overnight. Filter through sterile 0.2µm syringe filter before use. Store at 4 °C.
Bovine Serum Albumin	Sinopharm Chemical Reagent		Dissolve in sterile PBS and filter using 0.2 µm syringe filter before use.
BCA assay kit	Pierce	23225	This kit was used to measure BSA release from PD-IPC scaffolds.
Human Recombinant Vascular Endothelial Growth Factor	R&D systems	293-VE	Dissolve growth factor in 0.2% heparin solution to a final concentration of 5 mg/ml.
Heparin Sodium Salt From Porcine	Sigma Aldrich	H3393	This can be replaced by another brand type. Dissolve heparin salt in sterile water at a final concentration of 1% and filter through 0.2 µm syringe filter before use.
Human Umbilical Vein Endothelial Cells (HUVEC)	Lonza	C2517A	This primary cell type was used in the assay to determine VEGF bioactivity after release from PD-IPC scaffolds.
Alamar blue	Life Technologies	DAL1025	This is used to measure cell metabolic activity. Incubate Alamar blue with cells and maintain in standard cell culture conditions for 2 to 4 hours. Measure absorbance at 570 nm to determine Alamar blue percent reduction, which is correlated to the cell activity.

ScanVac Coolsafe Lyophilizer	Labogene	7.001.200.060	This is a non-programmable freeze dryer that operates at -105 to -110 °C, This can be replaced by other standard lab lyophilizers.
Polycaprolactone (PCL)	Sigma Aldrich	181609	MW 65 kDa. This is no longer being manufactured by Sigma Aldrich. This can be replaced by Sigma Aldrich catalog number 704105.
Dichloromethane	Sigma Aldrich	V800151	This can be replaced by another brand type. This material is hazardous and must be handled in the fume hood. Protective equipment must be worn at all times when handling this chemical.
Polydimethylsiloxane (PDMS; 184 Silicone Elastomer Kit)	Dow Corning	(240)4019862	The elastomer kit comes with polymer base and crosslinker. Mixing the polymer base and crosslinker in different ratios will result in different stiffness of the PDMS.
Human Recombinant Beta-Nerve Growth Factor (NGF)	R&D systems	256-GF	Reconstituted in sterile DI water to a final concentration of 100 µg/ml. Aliquot and store in -20 °C until use.
Human Mesenchymal Stem Cells (hMSC)	Cambrex		This cell type was used in the assay to determine synergistic effect of NGF and nanotopography.
Rat PC12 Pheochromocytoma Cells	ATCC		This cell type was used in the neurite outgrowth assay to determine bioactivity of NGF. After exposure to release media with NGF, measure number of cells with neurite extensions and normalize to total number of cells.

Grade 93 filter paper	Whatman	Z699675	This is used for the purification of chitosan after its precipitation with sodium hydroxide at pH 7.
Swing bucket centrifuge	Eppendorf	5810R	To be used during the purification of chitosan using 1200 x g speed.
Motor with mandrel rotating at constant speed	Rhymebus	RM5E	The motor is used for the fabrication of IPC fibers on pullulan or PCL frame.
Phosphate buffered saline	FirstBase		Sterilize through filtration (0.2 µm filter) and autoclave.
10-mm diameter Tissue Culture Polystyrene Dish (TCPS)	Greiner		The TCPS dish is used for casting of pullulan frame.
Human VEGF ELISA kit	R&D systems	DVE00	The ELISA kit is used for detection of VEGF in the release medium.
Human NGF ELISA kit	R&D systems	DY256	The ELISA kit is used for detection of NGF in the release medium.
Plastic Coated Adhesive Tape	Bel-Art	9040336	The adhesive tape is used to securely stick the alligator clip to the rotating mandrel



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: **Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules**

Author(s): **MFA CUTIONGCO, BKK TEO, EKF YIM**

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box): **Text**

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: **Evelyn KF Yim**
Department: **Department of Biomedical Engineering; Department of Surgery; Mechanobiology Institute**
Institution: **National University of Singapore**
Article Title: **Composite scaffolds of interfacial polyelectrolyte fibers for temporally controlled release of biomolecules**
Signature:  Date: **29 Dec 2014**

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

We thank the editorial office for their comments. We have responded to each comment in [blue](#).

Editorial comments:

1. Please provide details in all the protocol steps. For instance, in step 1.4: How much chitosan? How is the chitosan exposed to UV?
2. In step 1.3: How much alginic acid sodium salt?
3. In step 3.1.2: When was the pullulan solution frozen?
4. In step 3.2.1: How is the frame affixed?
5. Step 6.2: How concentrated should the cells be?

[We have added more details in the protocol, including all the steps mentioned in comments number 1 to 5 above. The material list was also updated to reflect the changes in the protocol.](#)

6. In Figures 2-, Please define the error. and please mention the units in the figure legends.

[We have added the required information in Figure 2 legend on page 7.](#)

7. Results: Please cite all figures in the text (like Figure 2) where they are discussed.

[We have added the citation to Figure 2 in the text.](#)

8. In discussion section, What are the critical steps and limitations of the protocol?

[The choice of the polymeric scaffold is critical in determining which biomolecules can have temporally-controlled release. We also included the requirement for the sacrificial frame to have the capacity for assimilation into the bulk scaffold. Both items were added in page 9 of the manuscript. The lack of mechanical strength of IPC fibers is also a critical drawback of IPC fiber formation thereby necessitating its incorporation in a composite scaffold, which has been included in page 10 of the manuscript.](#)

9. In references: Journal titles should be abbreviated.

[The references have been amended to show abbreviated journal titles.](#)

10. Please keep the editorial comments from your previous revisions in mind as you revise your manuscript to address peer review comments. For instance, if formatting or other changes were made, commercial language was removed, etc., please maintain these overall manuscript changes.

Track changes were turned on to monitor all revisions in the manuscript.

11. Please take this opportunity to thoroughly proofread your manuscript to ensure that there are no spelling or grammar issues. Your JoVE editor will not copy-edit your manuscript and any errors in your submitted revision may be present in the published version.

Thank you for the reminder. We have proof-read the manuscript again and kept the changes tracked in this iteration.

12. If your figures and tables are original and not published previously, please ignore this comment. For figures and tables that have been published before, please include phrases such as “Re-print with permission from (reference#)” or “Modified from..” etc. And please send a copy of the re-print permission for JoVE’s record keeping purposes.

Thank you for the reminder. We have obtained permission from Elsevier to reprint specific figures from our previous paper (Cutiongco et al., 2014). Meanwhile, Mary Ann Liebert does not require permission for authors to reuse their own work, which is applicable for our previous publication by Teo et al (2014). We have attached the evidence for re-print permission in this revision.

* JoVE reference format requires that DOIs are included, when available, for all references listed in the article. This is helpful for readers to locate the included references and obtain more information. Please note that often DOIs are not listed with PubMed abstracts and as such, may not be properly included when citing directly from PubMed. In these cases, please manually include DOIs in reference information.

DOI for all references have been manually added to the reference list.

We thank the reviewers for their positive feedback on our manuscript. We have responded to each of the comments in [blue](#).

Reviewers' comments:

Reviewer #1:

The present paper describes how IPC fibers can be incorporated into scaffolds composed of other polymers, namely dextran-pullulan and polycaprolactone, to form composite materials with sustained release capability. In addition, the methodology describes how the laying of IPC fibers with the aid of a microfabricated substrate and sacrificial matrix allows alignment of the fibers.

While the properties of IPC fibers, which are formed by polyelectrolyte complexation at the interface of two oppositely charged polymers for controlled release of growth factors has previously been reported, methods of incorporating these into tissue engineering scaffolds have not been developed. The authors further show how the IPC fibers can be aligned on fabricated scaffolds with nano-sized gratings structure to promote neural differentiation with simultaneous growth factor release.

The experiments were well designed and executed, while the paper itself is well written and organized. The necessary growth factor release profiles, assessment of bioactivity, as well as other methodology and results have been clearly presented.

The authors have convincingly shown how IPC fibers can be used for sustained delivery of biomolecules with good incorporation efficiency and retention of bioactivity, which compare favourably to conventional systems such as microspheres.

Page 7, Line 280: suggested change to `...lower in hMSCs cultured on PCL-IPC with `only' NGF release or patterned PCL' would clarify the sample type

As a whole, the paper forms an important contribution to the existing literature on applications of IPC fibers.

[We thank the reviewer for the encouraging and positive comments on our study. We have changed page 7, line 280 accordingly.](#)

Reviewer #2:

Manuscript Summary:

The authors prepared pullan/dextran scaffolds/PCL scaffolds containing IPC fibers

Major Concerns:

The authors did not clearly explain why pullan and dextran were employed to fabricate scaffolds over other polysaccharides.

Pullulan-dextran hydrogel was chosen because of the unique crosslinking mechanism that occurs in aqueous and ambient conditions, as added in page 10 of the manuscript.

Why did the authors prepare IPC fibers composed of chitosan and alginate, which are also polysaccharides.

Chitosan and aliginate are both natural polysaccharides with high charge density and mimicking the natural carbohydrates of animal ECM. Chitosan and alginate were used as a proof-of-concept for fabricating IPC fibers. We have added this information in page 9 of the manuscript.

In Figure 3B, the discussion on the result at day 3,6, and 8 should be included.

We have expanded the discussion of Figure 3B in page 7 of the manuscript.

There is no panel C in Figure 4, however, the figure caption is indicating 'C'.

We apologize for the mistake. Figure 4 caption has been amended.

Minor Concerns:

N/A

Additional Comments to Authors:

N/A

Elsevier permission to reproduce figures (as requested by JoVE)

[Click here to download Supplemental File \(as requested by JoVE\): PD paper_license for reuse.pdf](#)

MA Liebert permission to re-use figures (as requested by JoVE)

[Click here to download Supplemental File \(as requested by JoVE\): TEA paper_license for reuse.pdf](#)